$3.51
+0.15 (+4.46%)
Open$3.42
Previous Close$3.36
Day High$3.64
Day Low$3.37
52W High$49.66
52W Low$28.58
Volume—
Avg Volume711.8K
Market Cap131.89M
P/E Ratio40.15
EPS$0.99
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,350.7% upside
Current
$3.51
$3.51
Target
$50.92
$50.92
$37.48
$50.92 avg
$70.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.00M | 17.09M | 20.29M |
| Net Income | -5,617,065 | -4,142,594 | -5,000,058 |
| Profit Margin | -29.6% | -24.3% | -24.7% |
| EBITDA | -7,619,084 | -7,262,848 | -9,094,907 |
| Free Cash Flow | -5,290,454 | -5,494,601 | -5,886,545 |
| Rev Growth | -4.6% | +9.1% | +5.4% |
| Debt/Equity | 0.34 | 0.31 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |